These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
223 related items for PubMed ID: 10829311
1. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?]. Hölscher AH, Metzger R, Schneider PM. Zentralbl Chir; 2000; 125(4):319-25. PubMed ID: 10829311 [Abstract] [Full Text] [Related]
2. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, Mueller RP, Hoelscher AH, Schneider PM. Clin Cancer Res; 2005 Dec 01; 11(23):8341-7. PubMed ID: 16322294 [Abstract] [Full Text] [Related]
3. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Ann Surg Oncol; 2008 Oct 01; 15(10):2894-902. PubMed ID: 18663531 [Abstract] [Full Text] [Related]
4. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Ann Surg Oncol; 2010 Apr 01; 17(4):1159-67. PubMed ID: 20140529 [Abstract] [Full Text] [Related]
5. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR. Cancer; 2006 May 15; 106(10):2119-27. PubMed ID: 16607651 [Abstract] [Full Text] [Related]
6. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP. Ann Surg; 2009 Mar 15; 249(3):392-6. PubMed ID: 19247024 [Abstract] [Full Text] [Related]
7. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP. Ann Thorac Surg; 2008 Jun 15; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797 [Abstract] [Full Text] [Related]
8. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W. Ann Surg; 2010 Nov 15; 252(5):744-9. PubMed ID: 21037429 [Abstract] [Full Text] [Related]
10. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH. Ann Surg; 2008 Dec 15; 248(6):902-8. PubMed ID: 19092334 [Abstract] [Full Text] [Related]
11. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH. Ann Surg; 2005 Nov 15; 242(5):684-92. PubMed ID: 16244542 [Abstract] [Full Text] [Related]
12. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH. Ann Surg Oncol; 2010 Dec 15; 17(12):3187-94. PubMed ID: 20585867 [Abstract] [Full Text] [Related]
13. [Current diagnosis and therapy of esophageal carcinoma]. Mühr-Wilkenshoff F, Stahl M, Faiss S, Zeitz M, Scherübl H. Z Gastroenterol; 2004 Jul 15; 42(7):615-21. PubMed ID: 15248111 [Abstract] [Full Text] [Related]
14. Role of neoadjuvant therapy for esophageal adenocarcinoma. Ku GY, Ilson DH. Surg Oncol Clin N Am; 2009 Jul 15; 18(3):533-46. PubMed ID: 19500742 [Abstract] [Full Text] [Related]
15. [The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis]. Mücke R, Ziegler PG, Libera T, Klautke G, Fietkau R. Strahlenther Onkol; 2000 Aug 15; 176(8):350-5. PubMed ID: 10987017 [Abstract] [Full Text] [Related]
16. Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study. Davies L, Lewis WG, Arnold DT, Escofet X, Blackshaw G, Gwynne S, Evans M, Roberts SA, Appadurai I, Crosby TD. Clin Oncol (R Coll Radiol); 2010 Sep 15; 22(7):578-85. PubMed ID: 20591633 [Abstract] [Full Text] [Related]
19. [Esophageal carcinoma in an advanced stage. The value of surgery plus radiochemotherapy]. Theisen J, Siewert JR. MMW Fortschr Med; 2002 Jul 11; 144(27-28):36-8. PubMed ID: 12198876 [No Abstract] [Full Text] [Related]
20. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? Elsaleh H, Farrell JJ, Crane CH. J Gastroenterol Hepatol; 2009 May 11; 24(5):708-10. PubMed ID: 19646012 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]